Search Results

The product title you are looking for is no longer available. Other similar products that may interest you are listed below:

Refine your Search

Results for 'ChemoCentryx Inc -Company Report'
Title Publication Date Price Relevance
ChemoCentryx, Inc.-Therapeutic Competitors Report Mar 2011 £220 100%
Restenosis - Pipeline Review
H2 2011
 Aug 2011 £315 79%
Vasculitis - Pipeline Review
H2 2011
 Nov 2011 £315 79%
Celiac Disease Global Clinical Trials Review
Q2, 2011
 Jun 2011 £630 74%
Crohn's Disease Global Clinical Trials Review
Q2, 2011
 Jun 2011 £630 74%
Cardiovascular Inflammation Global Clinical Trials Review
H2, 2011
 Nov 2011 £630 73%
Inflammatory Bowel Disease Therapeutics Apr 2010 £2,500 72%
Spinal Surgery Oct 2011 £2,845 70%
Astrocytoma - Pipeline Review
Q2 2011
 Apr 2011 £315 67%
Astrocytoma - Pipeline Review
H2 2011
 Aug 2011 £315 67%
Macular Degeneration - Pipeline Review
H2 2011
 Sep 2011 £315 67%
Systemic Lupus Erythematosus - Pipeline Review
H2 2011
 Sep 2011 £315 66%
Glioma - Pipeline Review
H1 2012
 Jan 2012 £325 66%
Glioblastoma Multiforme (GBM) - Pipeline Review
H1 2012
 Jan 2012 £325 65%
Multiple Sclerosis - Pipeline Review
H2 2011
 Sep 2011 £315 65%
Psoriasis - Pipeline Review
H2 2011
 Sep 2011 £315 57%
Rheumatoid Arthritis Therapeutics Feb 2010 £2,500 56%
Gastrointestinal Disorder Therapeutics to 2016
High Unmet Needs Triggering Strong Growth in Crohn's Disease and Irritable Bowel Syndrome Markets
 Jun 2010 £2,215 55%
Crohn's Disease - Pipeline Review
H2 2011
 Sep 2011 £315 55%
Rheumatoid Arthritis - Pipeline Review
H2 2011
 Sep 2011 £315 52%
Therapeutics and Biomaterials for Musculoskeletal Disease: Global Markets Jul 2010 £3,065 52%
Therapeutic/Diagnostic Devices for Neurological Disorders Jan 2007 £2,760 52%
Type 2 Diabetes - Pipeline Review
H2 2011
 Sep 2011 £315 51%
U.S. Market for Gastrointestinal Pharmaceuticals Sep 2005 £2,760 50%
Gastrointestinal Pharmaceuticals: Technologies and Markets Sep 2009 £3,065 50%
Diabetes - Pipeline Review
H2 2011
 Oct 2011 £315 48%